RxDoctor Payments Data

Jennifer King, PA

Physician Assistant · Muskegon, MINPI 1497301311

Payments from drug & device makers

$3,042in general payments, 2019–2025

Across 130 payments — averaging $23.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Biohaven Pharmaceuticals, Inc.$423
  • Biohaven Pharmaceutical Holding Company Ltd.$358
  • Amgen$210
  • Impel Pharmaceuticals Inc.$169
  • Lundbeck LLC$166
  • plus $680 from 16 others

What the payments were for

  • Food & beverage$2,98998%
  • Education$532%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,042 in reported general payments places this provider in the 90th percentile of 5,453 physician assistant providers in Michigan.

See all physician assistant providers in Michigan

Medicare billing

Part B allowed, 2024
$13,887
Medicare patients
103
Services billed
186

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine22$232,126
Aimovig AutoinjectorErenumab-Aooe134$101,236
UbrelvyUbrogepant21$29,943
Ajovy AutoinjectorFremanezumab-Vfrm37$24,760
Nurtec OdtRimegepant Sulfate22$21,916
Trokendi XrTopiramate11$13,597
Emgality PenGalcanezumab-Gnlm16$11,881
Emgality SyringeGalcanezumab-Gnlm12$9,339
Methazolamide11$3,032
Primidone42$2,827
Carbidopa-LevodopaCarbidopa/Levodopa73$2,605
Propranolol Hcl ErPropranolol Hcl76$2,023
Lacosamide28$1,867
Divalproex Sodium ErDivalproex Sodium16$1,323
Memantine Hcl30$1,202

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$166$232,12622 claims
AbbVieUbrelvy$1,037$29,94321 claims
PfizerNurtec Odt$17$21,91622 claims
Upsher-smith Laboratories LLCTopiramate$58$1,05787 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,453 physician assistant providers in Michigan.

Other physician assistant in Muskegon

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →